2.375

0.85% 0.025

Abcellera Biologics Inc (ABCL)

Overview News Price History Option Chain Financials Why ABCL Down? Discussions Forecast

Abcellera Biologics Inc stock is traded at $2.375, with a volume of 1.39M. It is up +0.85% in the last 24 hours and down -24.52% over the past month. AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Previous Close:

$2.35

Open:

$2.34

24h Volume:

1.39M

Relative Volume:

0.37

Market Cap:

$692.82M

Revenue:

$38.03M

Net Income/Loss:

$-146.40M

P/E Ratio:

-4.5673

EPS:

-0.52

Net Cash Flow:

$-121.38M

1W Performance:

-0.42%

1M Performance:

-24.52%

6M Performance:

-13.82%

1Y Performance:

-51.73%

1-Day Range:

$2.31

$2.38

1-Week Range:

$2.11

$2.4097

52-Week Range:

$2.11

$4.93

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name

Abcellera Biologics Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

(604) 559-9005

Address

2215 YUKON STREET, VANCOUVER

Employee

596

Twitter

Next Earnings Date

2024-11-18

Latest SEC Filings

ABCL's Discussions on Twitter

Compare ABCL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABCL Abcellera Biologics Inc	2.375	692.82M	38.03M	-146.40M	-121.38M	-0.52
VRTX Vertex Pharmaceuticals Inc	501.68	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	681.50	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	579.21	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.18	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.47	26.76B	3.32B	-860.46M	-1.04B	-8.32

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-20-24	Downgrade	The Benchmark Company	Buy → Hold
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy
Nov-16-22	Initiated	Truist	Buy
Dec-21-21	Initiated	The Benchmark Company	Buy
Nov-19-21	Initiated	Piper Sandler	Overweight
Jan-05-21	Initiated	BMO Capital Markets	Outperform
Jan-05-21	Initiated	Berenberg	Buy
Jan-05-21	Initiated	Credit Suisse	Outperform
Jan-05-21	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	Stifel	Buy

View All

Abcellera Biologics Inc Stock (ABCL) Latest News

Mar 12, 2025

What To Expect From AbCellera Biologics Inc (ABCL) Q4 2024 Earni - GuruFocus.com

Mar 12, 2025

Mar 11, 2025

Thermopylae holdings acquires $742,242 in AbCellera shares - Investing.com India

Mar 11, 2025

Major Stakeholder Makes Bold Move with AbCellera Biologics Stock Purchase! - TipRanks

Mar 11, 2025

Mar 10, 2025

AbCellera biologics director John Montalbano acquires $57,499 in shares By Investing.com - Investing.com South Africa

Mar 10, 2025

AbCellera biologics director John Montalbano acquires $57,499 in shares - Investing.com India

Mar 10, 2025

Abcellera stock hits 52-week low at $2.20 amid market challenges - Investing.com

Mar 10, 2025

Mar 09, 2025

Independent Non-Employee Director of AbCellera Biologics Picks Up 66% More Stock - Simply Wall St

Mar 09, 2025

Mar 07, 2025

Director Makes Bold Move with Major Stock Purchase in AbCellera Biologics - TipRanks

Mar 07, 2025

Abcellera Biologics director Montalbano buys $140,568 in shares By Investing.com - Investing.com South Africa

Mar 07, 2025

Abcellera Biologics director Montalbano buys $140,568 in shares - Investing.com

Mar 07, 2025

Mar 06, 2025

Q1 Earnings Estimate for ABCL Issued By Bloom Burton - Defense World

Mar 06, 2025

Mar 05, 2025

Sanctuary Advisors LLC Decreases Stake in AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World

Mar 05, 2025

Mar 04, 2025

AbCellera Biologics’ (ABCL) Hold Rating Reaffirmed at Benchmark - Defense World

Mar 04, 2025

Mar 03, 2025

Benchmark maintains Hold on AbCellera stock, no price target change - Investing.com

Mar 03, 2025

Benchmark maintains Hold on AbCellera stock, no price target change By Investing.com - Investing.com UK

Mar 03, 2025

Mar 01, 2025

Stifel Nicolaus Issues Pessimistic Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price - MarketBeat

Mar 01, 2025

AbCellera Biologics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK

Mar 01, 2025

AbCellera Biologics (NASDAQ:ABCL) Reaches New 52-Week Low on Analyst Downgrade - MarketBeat

Mar 01, 2025

Feb 28, 2025

AbCellera Biologics (ABCL) Projected to Post Earnings on Thursday - MarketBeat

Feb 28, 2025

AbCellera Biologics (NASDAQ:ABCL) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat

Feb 28, 2025

AbCellera Biologics (NASDAQ:ABCL) Posts Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat

Feb 28, 2025

AbCellera Biologics’ Earnings Call: Transition Amid Challenges - TipRanks

Feb 28, 2025

Abcellera stock hits 52-week low at $2.33 amid market challenges - Investing.com India

Feb 28, 2025